A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

NCT07205887

Status	RECRUITING
Phase	Phase 2
Sponsor	EyeBiotech Ltd.
Enrollment	160 participants

Key Eligibility Criteria

Inclusion (11)

- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- Be male or female e18 years of age.
- Be e 50 years of age
- Have treatment naive subfoveal CNV secondary to AMD or juxtafoveal/extrafoveal CNV with foveal involvement
- For participants who are treatment naïve for NVAMD, the diagnosis must have been made within 21 days prior to the Day 1 study treatment

... and 6 more (see full listing online)

Exclusion (8)

- Be pregnant or breastfeeding
- History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
- Have had Yttrium-Aluminum Garnet (YAG) laser capsulotomy in the study eye within 90 days of Screening
- Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
- Have had previous thermal subfoveal laser therapy in the study eye

... and 3 more (see full listing online)

Locations (49 total)

Scottsdale, Arizona, Scottsdale, Arizona, United States
Scottsdale, AZ, Scottsdale, Arizona, United States
Glendale, California, Glendale, California, United States
... and 46 more locations